Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

View:
Post by MinimumDamage on Mar 05, 2021 9:24am

Quick Recap

There's absolutely nothing proprietary in the DNA of the company. We do not own anything of value. All PARTIAL license agreements + a borrowed lab in Australia for a discount of 43%. MONTHLY AMBITIOUS announcements of additional programs. An intertwined team divided in a 3 way split of private companies.

Only holding the PARTIAL rights to R-107 for the treatment of coronaviruses and COVID-19 infection. Due to the cancelled acquisition, Salzman has retained all rights for CILI (Chlorine inhalation lung injury), PAH (Pulmonary arterial hypertension), getting your reproductive organ hard (erectile dysfunction) and everything else where acute lung injuries could be treated.

GVHD the previous soul and pumping blood of the whole enterprise, relinquished. Freedom of many liabilities, debt paiements and difficulty finding a larger Pharma company taking the project over were the main reasons that the project was terminated.

Live long and prosper, do the right thing, abandon ship and salvage the remainder of your investment while you still can.
Comment by AngelaL on Mar 05, 2021 9:34am
Your comment is nothing but rubbish. The company has a bulletproof license for R-107 as a treatment for Covid (read it, you can find it on Sedar). It would have nice to have acquired all of Salzman Group but that would have come at the price of a hefty dilution. The PR this week describing the strategic collaboration augurs well for a tight relationship where Claritas has all the benefits of the ...more  
Comment by Moonshiner592 on Mar 05, 2021 9:43am
Take a bow Angela!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities